Champions Oncology (CSBR) Non Operating Income (2010 - 2019)
Champions Oncology (CSBR) posted quarterly Non Operating Income of -$12000.0 for Q3 2019, down 1300.0% year-over-year from $1000.0 in Q3 2018, and up 64.71% quarter-over-quarter from -$34000.0 in Q2 2019.
Champions Oncology (CSBR) Non Operating Income (2010 - 2019) Analysis & Trends
Champions Oncology's Non Operating Income history runs 10 years deep, the most recent figure standing at -$12000.0 for Q3 2019.
- In Q3 2019, Non Operating Income fell 1300.0% year-over-year to -$12000.0; the TTM figure through Jul 2019 stood at -$52000.0 (down 40.54% YoY), while the FY2019 annual figure was -$39000.0, up 56.18% from the prior year.
- Non Operating Income for Q3 2019 stood at -$12000.0, up from -$34000.0 in the prior quarter.
- The five-year high for Non Operating Income was $615000.0 in Q1 2015, with the low at -$1.2 million in Q2 2015.
- The 5-year median for Non Operating Income is -$10000.0 (2015), against an average of -$41842.1.
- Peak annual rise in Non Operating Income reached 114.29% in 2019, while the deepest fall reached 1300.0% in 2019.
- Champions Oncology's Non Operating Income stood at -$14000.0 in 2015, then decreased by 14.29% to -$16000.0 in 2016, then climbed by 18.75% to -$13000.0 in 2017, then jumped by 46.15% to -$7000.0 in 2018, then sank by 71.43% to -$12000.0 in 2019.
- Business Quant data shows CSBR's Non Operating Income at -$12000.0 in Q3 2019, -$34000.0 in Q2 2019, and $1000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2019 | -12,000.00 |
| Apr 30, 2019 | -34,000.00 |
| Jan 31, 2019 | 1,000.00 |
| Oct 31, 2018 | -7,000.00 |
| Jul 31, 2018 | 1,000.00 |
| Apr 30, 2018 | -18,000.00 |
| Jan 31, 2018 | -7,000.00 |
| Oct 31, 2017 | -13,000.00 |
| Jul 31, 2017 | -51,000.00 |
| Apr 30, 2017 | -23,000.00 |
| Jan 31, 2017 | -8,000.00 |
| Oct 31, 2016 | -16,000.00 |
| Jul 31, 2016 | -9,000.00 |
| Apr 30, 2016 | -9,000.00 |
| Jan 31, 2016 | -8,000.00 |
| Oct 31, 2015 | -14,000.00 |
| Jul 31, 2015 | -10,000.00 |
| Apr 30, 2015 | -1.17 Mn |
| Jan 31, 2015 | 615,000.00 |
| Oct 31, 2014 | 598,000.00 |